Dexrazoxane
FDA Approved: * September 28, 2004Pharm Company: * BEDFORD
Category: Cancer
Dexrazoxane hydrochloride (Zinecard, Cardioxane) is a cardioprotective agent. It was discovered by Eugene Herman in 1972. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH.[1] Contents 1 Uses 2 Mechanism 3 References 4 External links Uses Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as anthracyclines,[2] such as daunorubicin or doxorubicin or other c... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.Dosage List
Dexrazoxane 10 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0143-9247
Labeler:
West-ward Pharmaceuticals Corp
Dexrazoxane 10 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 0143-9248
Labeler:
West-ward Pharmaceuticals Corp
Dexrazoxane 10 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 42605-029
Labeler:
Thymoorgan Gmbh Pharmazir & Co. K.g
Dexrazoxane 10 mg/ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 42605-030
Labeler:
Thymoorgan Gmbh Pharmazir & Co. K.g
Dexrazoxane 500 mg/50ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 47781-578
Labeler:
Alvogen Inc.
Dexrazoxane 500 mg/50ml Intravenous Injection, Solution
NDC: 51991-942
Labeler:
Breckenridge Pharmaceutical, Inc.
